Oxford Biomedica (OXB.L)

Trade OXB.L now with
9/15/2022 2:48:31 AM Oxford Biomedica 6-month Basic Loss Per Share 27.29p Vs Profit 21.92p Last Year
7/1/2022 2:13:58 AM Oxford Biomedica Signs 3-yr New Agreement With AstraZeneca
6/14/2022 2:33:02 AM Oxford Biomedica Says FDA Lifted Clinical Hold On Homology Medicines' PheNIX Trial
4/20/2022 2:20:23 AM Oxford BioMedica FY Total Revenues Up 63% Over 2020 To £142.8 Mln
4/13/2022 2:08:28 AM Oxford Biomedica Appoints Namrata Patel As Non-Executive Director
2/1/2022 2:11:46 AM Oxford Biomedica: Sio Gene Therapies Intends To Cease License Deal For Gene Therapy Programme In Parkinson's Disease
1/28/2022 2:40:44 AM Oxford Biomedica US To Buy 80% Interest In Oxford Biomedica Solutions' AAV Manufacturing And Innovation Business
1/17/2022 2:09:54 AM Oxford Biomedica CEO John Dawson Intends To Retire
1/5/2022 2:03:01 AM Oxford Biomedica Inks Licence And Supply Deal With Cabaletta Bio For LentiVector Platform
12/14/2021 2:15:01 AM Oxford Biomedica Appoints Catherine Moukheibir As Non-Executive Director
12/13/2021 2:08:32 AM Oxford Biomedica Extends Commercial Supply Deal For Manufacture Of Lentiviral Vectors To End Of 2028
12/13/2021 2:04:04 AM Oxford Biomedica Signs Licence & Supply Agreement With Arcellx For LentiVector Platform For CAR-T Therapeutics